FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

conditi	ons of Rule 10t tion 10.																		
1. Name and Address of Reporting Person* Schuchart Aaron						2. Issuer Name and Ticker or Trading Symbol LUMOS PHARMA, INC. [(LUMO)]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
	200 MARATHON BLVD				3. Date of Earliest Transaction (Month/Day/Year) 12/12/2024									Officer (give title Other (specify below) Chief Business Officer					
SUITE 200 (Street) AUSTIN TX 78756					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting					n
(City)	(S	tate)	(Zip)												Persor	1			
		Tak	ole I - Nor	n-Deriv	ative	e Se	curit	ties Ac	quired, [Disp	osed o	f, or Be	nefi	cially	Owned				
Date				Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Ir	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) o (D)	PI	ice	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)
Common Stock 12/12/					2/202	/2024			D		8,179	79 D		(1)	0			D	
			Table II -						uired, Di						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,		ansaction ode (Instr.		umber ivative urities uired or oosed O) (Instr. and 5)	Expiration	6. Date Exercisat Expiration Date Month/Day/Year		of Securitie		1	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirec Beneficia Ownershi (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amo or Num of Sha	ber					
Stock Option (Right to Buy)	\$3.52	12/12/2024			D			12,000	(2)		(2)	Common Stock	12,	000	(2)	0		D	
Stock Option (Right to Buy)	\$2.84	12/12/2024			D			12,000	(2)	0.	3/31/2034	Common Stock	12,	000	(2)	0		D	
Stock Option (Right to Buy)	\$9.06	12/12/2024			D			45,000	(3)	0	5/05/2030	Common Stock	45,	000	(3)	0		D	
Stock Option (Right to Buy)	\$10.02	12/12/2024			D			12,000	(3)	0	1/31/2032	Common Stock	12,	000	(3)	0		D	
Stock Option (Right to Buy)	\$10.13	12/12/2024			D			7,805	(3)	0	5/31/2031	Common Stock	7,8	05	(3)	0		D	
Stock Option (Right to Buy)	\$17.35	12/12/2024			D			8,500	(3)	0	1/31/2031	Common Stock	8,5	500	(3)	0		D	

Explanation of Responses:

- 1. Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) \$4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each restricted stock unit ("RSU") was cancelled and will receive the Cash Amount plus one CVR per RSU.
- 2. This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.
- 3. Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement

Remarks:

/s/ Ryan Trytten, attorney-infact

12/13/2024

** Signature of Reporting Person

Date

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.